TMPRSS2 and prostate carcinoma: For example, the BCR::ABL1 rearrangement of the Philadelphia chromosome has become an early biomarker for chronic and acute myeloid leukemias, as well as for monitoring in the case of a relapse or incomplete response [201]; in prostate cancer, TMPRSS2::ERG fusion detection has been suggested as a screening tool [202].